Research__O at__O the__O University__B-ORG of__I-ORG Liverpool__I-ORG has__O collectively__O improved__O understanding__O of__O the__O genetic__O basis__O of__O drug-induced__O hypersensitivity__O and__O provided__O "proof__O of__O principle"__O for__O the__O clinical__O use__O of__O genetic__O testing__O before__O prescribing__O drug__O therapy.__O
UoL__O research__O has__O contributed__O to__O changes__O in__O the__O prescribing__O information__O for__O two__O widely__O used__O drugs,__O carbamazepine__O and__O abacavir.__O
The__O prescribing__O information__O has__O been__O revised__O to__O include__O information__O on__O the__O genetic__O predisposing__O factors__O to__O hypersensitivity__O reactions__O caused__O by__O these__O two__O drugs;__O clinical__O guidelines__O have__O also__O been__O changed__O for__O abacavir__O to__O reflect__O the__O need__O for__O genotyping__O prior__O to__O drug__O administration.__O
The__O research__O has__O impacted__O on__O the__O clinical__O care__O and__O lives__O of__O patients__O with__O chronic__O diseases__O such__O as__O epilepsy,__O bipolar__O disorder,__O neuropathic__O pain__O and__O AIDS.__B-ORG
Therapy__B-ORG has__O been__O optimised__O by__O individualising__O drug__O prescription__O to__O a__O patient__O based__O on__O key__O characteristics__O such__O as__O genetic__O factors.__O
This__O reduces__O the__O risk__O of__O severe__O and__O potentially__O fatal__O ADRs.__B-ORG
Abacavir__O hypersensitivity__O The__O study__O showed__O that__O it__O would__O be__O cost-effective__O to__O undertake__O pre-treatment__O screening__O for__O HLA-__O B*57:01__O to__O predict__O susceptibility__O to__O abacavir__O hypersensitivity__O [2].__O
This__O has__O led__O to__O the__O following__O impacts.__O
Clinical__O guidelines__O from__O societies,__O e.g.__O
the__O British__B-MISC HIV__I-MISC Association,__I-MISC were__O changed__O in__O 2008__O to__O recommend__O testing__O for__O HLA-B*57:01__B-ORG before__O the__O use__O of__O abacavir__O [7].__O
This__O is__O now__O well__O established__O in__O NHS__O practice.__O
The__O drug__O labels__O (i.e.__O
prescribing__O information)__O were__O changed__O in__O the__O US,__B-MISC EU__B-ORG and__O Australia__B-LOC after__O 2008__O to__O recommend__O the__O use__O of__O HLA-B*57:01__B-ORG genotyping__O prior__O to__O the__O use__O of__O abacavir__O [8-10].__O
The__O evidence__O from__O the__O UoL__B-ORG study__O was__O used__O by__O the__O NHS__B-ORG to__O implement__O the__O use__O of__O the__O HLA-B*57:01__B-MISC testing__O in__O HIV__B-MISC clinics__O from__O 2006.__O
This__O has__O led__O to__O a__O marked__O reduction__O of__O the__O incidence__O of__O abacavir__O hypersensitivity__O (from__O 7.8%__O to__O 2%__O [11]).__O
It__O is__O now__O rare__O to__O see__O any__O cases__O of__O abacavir__O hypersensitivity__O in__O clinical__O practice__O to__O the__O benefit__O of__O patients__O &#8212;__O this__O has__O been__O demonstrated__O in__O a__O publication__O from__O the__O Chelsea__B-ORG and__O Westminster__B-MISC HIV__I-MISC clinic__O which__O showed__O that__O the__O incidence__O of__O hypersensitivity__O had__O gone__O down__O from__O 7.8%__O to__O 2%__O [11]__O The__O number__O of__O HLA-B*57:01__B-MISC genetic__O tests__O undertaken__O in__O the__O NHS__B-ORG rose__O sharply__O after__O 2006,__O and__O at__O the__O same__O time__O the__O use__O of__O abacavir__O also__O increased__O (see__O figure),__O and__O continues__O to__O the__O present__O day.__O
Most__O of__O the__O HLA-B*57:01__B-MISC testing__O was__O provided__O by__O Delphic__B-PER Diagnostics,__I-PER a__O University__B-ORG of__I-ORG Liverpool__I-ORG spin-out__O company__O (co-founders__O were__O Prof__B-PER Khoo__I-PER and__O Back,__B-LOC Dept__I-LOC of__O Pharmacology,__B-LOC UoL).__I-LOC
Delphic__O was__O bought__O out__O by__O Lab21__B-PER in__O 2009.__O
Total__O number__O of__O tests__O in__O 2007-08__O and__O 2008-09__O were__O 3,493__O (revenue__O &#163;186,850)__O and__O 1,908__O (&#163;100,630)__O respectively.__O
Figure:__O The__O increase__O in__O HLA__B-ORG testing__O and__O at__O the__O same__O time,__O the__O rise__O in__O the__O use__O of__O abacavir__O (kivexa)__O The__O importance__O of__O this__O work__O is__O confirmed__O by__O a__O case__O study__O by__O The__B-ORG Academy__I-ORG of__I-ORG Medical__I-ORG Sciences__I-ORG in__O 2012__O [12].__O
Pre-prescription__O genotyping__O for__O HLA-B*57:01__O is__O now__O used__O in__O most__O countries__O and__O has__O also__O been__O shown__O to__O improve__O clinical__O outcomes__O (i.e.__O
reduce__O hypersensitivity)__O in__O Australia__B-LOC and__O France,__B-LOC and__O has__O been__O shown__O to__O be__O cost-effective__O in__O several__O countries__O including__O the__O US__B-LOC and__O Germany.__B-LOC
Carbamazepine__O hypersensitivity__O UoL__B-MISC research__O showed__O susceptibility__O to__O carbamazepine__O hypersensitivity__O reactions__O in__O Caucasian__B-ORG patients__O was__O localised__O to__O the__O MHC,__B-ORG but__O that__O the__O risk__O factor__O in__O Caucasians__B-LOC was__O distinct__O to__O that__O demonstrated__O in__O Chinese__B-MISC patients__O [3].__O
Thus,__O in__O Caucasians,__B-PER HLA-B*1502,__I-PER is__O not__O a__O risk__O factor__O for__O SJS/TEN__O and__O for__O hypersensitivity__O syndrome,__O two__O distinct__O phenotypes__O associated__O with__O carbamazepine__O treatment.__O
This__O publication__O was__O utilised__O by__O the__O FDA,__B-ORG who__O in__O December__O 2007,__O recommended__O that__O patients__O of__O Asian__B-MISC ancestry,__O but__O not__O Caucasians,__B-MISC should__O be__O tested__O for__O HLA-B*1502__B-ORG prior__O to__O the__O start__O of__O carbamazepine__O therapy__O [13].__O
The__O drug__O label__O was__O also__O changed__O in__O the__O EU__B-ORG in__O 2008,__O again__O recommending__O the__O use__O of__O testing__O in__O Asian__B-MISC patients,__O but__O not__O in__O Caucasians__B-LOC [14].__I-LOC
The__O continuing__O work__O of__O UoL__B-ORG in__O this__O area__O has__O recently__O identified__O HLA-A*31:01__O as__O a__O genetic__O risk__O factor__O for__O carbamazepine-induced__O hypersensitivity__O reactions__O in__O Caucasians__B-LOC [5].__I-LOC
The__O prescribing__O information__O for__O carbamazepine__O has__O been__O changed__O in__O Japan,__B-LOC in__O the__O EU__B-ORG and__O in__O the__O US__B-LOC since__O 2011__O making__O prescribers__O aware__O of__O the__O association__O between__O this__O allele__O and__O carbamazepine__O hypersensitivity__O in__O Caucasians__B-LOC [15].__I-LOC
In__O 2010,__O the__O UoL__B-ORG became__O the__O global__O co-ordinating__O centre__O for__O the__O International__B-ORG Consortium__I-ORG on__I-ORG Drug__I-ORG Hypersensitivity__I-ORG (ITCH),__I-ORG sponsored__O by__O the__O International__B-ORG Serious__I-ORG Adverse__I-ORG Events__I-ORG Consortium__I-ORG (iSAEC)__I-ORG (http://www.saeconsortium.org/).__O
We__O have__O now__O recruited__O 1500__O patients__O with__O hypersensitivity__O reactions__O from__O 12__O international__O centres,__O and__O 50__O UK__B-LOC centres.__O
In__O 2013,__O we__O were__O awarded__O an__O i4i__O grant__O from__O the__O NIHR__B-ORG in__O collaboration__O with__O MC__O Diagnostics__O to__O develop__O a__O HLA-testing__O biomarker__O panel__O which__O can__O simultaneously__O test__O for__O multiple__O HLA__B-ORG alleles__O at__O a__O low__O cost__O (&lt;&#163;20)__B-MISC with__O turnaround__O time__O of__O &lt;48h.__B-LOC
